2.81
price up icon4.46%   0.12
after-market Dopo l'orario di chiusura: 2.82 0.010 +0.36%
loading

Inozyme Pharma Inc Borsa (INZY) Ultime notizie

pulisher
Nov 22, 2024

Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World

Nov 22, 2024
pulisher
Nov 21, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Nov 21, 2024
pulisher
Nov 20, 2024

Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN

Nov 20, 2024
pulisher
Nov 17, 2024

Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St

Nov 17, 2024
pulisher
Nov 15, 2024

Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com

Nov 14, 2024
pulisher
Nov 11, 2024

Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire

Nov 11, 2024
pulisher
Nov 11, 2024

Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 10, 2024

Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 10, 2024
pulisher
Nov 09, 2024

Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World

Nov 09, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World

Nov 08, 2024
pulisher
Nov 08, 2024

Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat

Nov 06, 2024
pulisher
Nov 06, 2024

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada

Nov 05, 2024
pulisher
Nov 05, 2024

Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 05, 2024
pulisher
Nov 05, 2024

Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan

Nov 05, 2024
pulisher
Oct 27, 2024

Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat

Oct 27, 2024
pulisher
Oct 27, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World

Oct 27, 2024
pulisher
Oct 25, 2024

Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Inozyme reports positive trial results for kidney disease therapy - Investing.com India

Oct 25, 2024
pulisher
Oct 24, 2024

Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada

Oct 24, 2024
pulisher
Oct 24, 2024

Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch

Oct 24, 2024
pulisher
Oct 24, 2024

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire

Oct 24, 2024
pulisher
Oct 21, 2024

The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 21, 2024
pulisher
Oct 18, 2024

(INZY) Proactive Strategies - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 18, 2024

Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria

Oct 18, 2024
pulisher
Oct 17, 2024

Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com

Oct 17, 2024
pulisher
Oct 17, 2024

Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat

Oct 16, 2024
pulisher
Oct 12, 2024

Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 12, 2024
pulisher
Oct 12, 2024

Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat

Oct 10, 2024
pulisher
Oct 08, 2024

Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Inozyme Pharma appoints new board member - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Welcomes New Director Erik Harris - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme appoints Erik Harris to board of directors - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News

Oct 07, 2024
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Capitalizzazione:     |  Volume (24 ore):